Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass

Diabetes Technology and Therapeutics

Volumn 7, Issue 4, 2005, Pages 651-657

  Gallwitz, B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CJC 1131; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

APOPTOSIS; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; DRUG DEGRADATION; DRUG EFFECT; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; INSULIN RELEASE; NAUSEA; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL; REVIEW; SATIETY; STOMACH EMPTYING; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; ISLETS OF LANGERHANS; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SATIATION;

EID: 23944484014     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2005.7.651     Document Type: Review

References (38)

1. Creutzfeldt W: The incretin concept today. Diabetologia 1979;16:75-85.
2. Creutzfeldt W: Entero-insular axis and diabetes mellitus. Horm Metab Res Suppl 1992;26:13-18.
3. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B: Gastric inhibitory polypeptide: The neglected incretin revisited. Regul Pept 2002;107:1-13.
4. Nauck MA, Hornberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-498.
5. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987;2:1300-1304.
6. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C: Proglucagon processing in porcine and human pancreas. J Biol Chem 1994;269:18827-18833.
7. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauchk MA: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-2725.
8. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
9. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002;359:824-830.
10. Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C: Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 2004;287:R562-R567.
11. Gutzwiller JP, Degen L, Heuss L, Beglinger C: Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 2004;82:17-19.
12. Perfetti R, Hui H: The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004;36:804-810.
13. Brubaker PL, Drucker DJ: Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-2659.
14. Drucker DJ: Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-171.
15. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL: Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004;47:478-487.
16. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB: GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-132.
17. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA: Exenatide (exendin-4) improves insulin sensitivity and (beta)-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005;146:2069-2076.
18. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003;52:751-759.
19. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-2377.
20. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-5158.
21. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744.
22. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-1342.
23. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214: 829-835.
24. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998;41:271-278.
25. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
26. Joy SV, Rodgers PT, Scates AC: Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005;39:110-118.
27. Meier JJ, Gallwitz B, Nauck MA: Glucagon-like peptide 1 and gastric inhibitory polypeptide: Potential applications in type 2 diabetes mellitus. BioDrugs 2003;17:93-102.
28. Baggio LL, Huang Q, Brown TJ, Drucker DJ: A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-2500.
29. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2628-2635.
30. Gallwitz B, Witt M, Paetzold G, Morys-Wortmann C, Zimmermann B, Eckart K, Folsch UR, Schmidt WE: Structure/activity characterization of glucagon-like peptide-1. Eur J Biochem 1994;225:1151-1156.
31. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke BL: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268: 19650-19655.
32. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
33. Mark M: NN-2211 Novo Nordisk. IDrugs 2003;6: 251-258.
34. Harder H, Nielsen L, Tu DT, Astrup A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-1921.
35. Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2874-2880.
36. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE: 1-[[(3-Hydroxy-1l-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-2789.
37. Deacon CF, Holst JJ: Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: A historical perspective. Biochem Biophys Res Commun 2002;294:1-4.
38. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.